Patents by Inventor Ying-Hua CHANG

Ying-Hua CHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12249599
    Abstract: Multiple chip module (MCM) structures are described. In an embodiment, a module includes a first and second components on the top side of a module substrate, a stiffener structure mounted on the top side of the module substrate, and a lid mounted on the stiffener structure and covering the first component and the second component. The stiffener is joined to the lid within a trench formed in a roof of the lid.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: March 11, 2025
    Assignee: Apple Inc.
    Inventors: Wei Chen, Jie-Hua Zhao, Jun Zhai, Po-Hao Chang, Hsien-Che Lin, Ying-Chieh Ke, Kunzhong Hu
  • Publication number: 20240269312
    Abstract: Provided in the present application are an antibody-drug conjugate, and a preparation method therefor and the use thereof. The antibody drug conjugate has a structure as represented by the formula Ab-[M-L-E-D]x, and the drug is selected from an anti-tubulin agent, a DNA intercalator, a DNA topoisomerase inhibitor and a RNA polymerase inhibitor. The prepared antibody-drug conjugate has a better drug-to-antibody ratio, and has a good targeted killing effect on colon cancer and non-small cell lung cancer (for example, lung adenocarcinoma).
    Type: Application
    Filed: May 23, 2022
    Publication date: August 15, 2024
    Applicants: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., KLUS PHARMA INC.
    Inventors: Haijun TIAN, Qiang TIAN, Xiaoxi YUAN, Ying-Hua CHANG, Deliang LI, Jiangjiang HU, Yitao ZHANG, Xiaobei WANG, Yong ZHENG, Jian YE, Bo WANG, Yu MIAO, Bingqiang KANG, Fen LI, Zujian TANG, Hanwen DENG, Hongmei SONG, Junyou GE, Jingyi WANG
  • Publication number: 20240018237
    Abstract: The present invention relates to the field of treatment of diseases. Specifically, the present invention relates to an anti-ROR1 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding same, and methods for preparing same. The anti-ROR1 antibody or the antigen-binding fragment thereof of the present invention has high specificity and high affinity for ROR1, and can effectively bind ROR1 and mediate killing of ROR1 expression cells. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in preparation of a drug which is used for prevention and/or treatment of tumors.
    Type: Application
    Filed: February 28, 2022
    Publication date: January 18, 2024
    Applicants: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., KLUS PHARMA INC.
    Inventors: Haijun TIAN, Yangde CHEN, Ying-Hua CHANG, Zhiqiang ZHU, Wenhui WU